Arcutis Biotherapeutics (ARQT) Stock Statistics & Valuation Metrics

Arcutis Biotherapeutics has a market cap or net worth of $1.81B. The enterprise value is $1.62B.

Arcutis Biotherapeutics has 118,638,240 shares outstanding. The number of shares has decreased by -2.65% in one year.

Arcutis Biotherapeutics’s return on equity (ROE) is -0.89 and return on invested capital (ROIC) is -47.86%.

The current PE Ratio of Arcutis Biotherapeutics is -12.03. Arcutis Biotherapeutics’s PEG ratio is 0.17.

In the last 12 months, Arcutis Biotherapeutics had revenue of 196.54M and earned -140.04M in profits. Earnings per share was -1.16.

In the last 12 months, operating cash flow was -112.16M and capital expenditures -5.14M, giving a free cash flow of -117.30M billion.

Arcutis Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Arcutis Biotherapeutics upcoming earnings date is May 6, 2025, TBA Not Confirmed.

Arcutis Biotherapeutics as a current ratio of 4.15, with Debt / Equity ratio of 70.19%

In the past 12 months, Arcutis Biotherapeutics has paid 647.00K in taxes.

Arcutis Biotherapeutics EV to EBITDA ratio is -14.75, with an EV/FCF ratio of -14.40.

Arcutis Biotherapeutics has $227.96M in cash and marketable securities with ― in debt, giving a net cash position of -$117.37M billion.

Gross margin is 90.27%, with operating margin of -65.33%, and net profit margin of -71.25%.

The average price target for Arcutis Biotherapeutics is $19.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy